報價延遲最少15分鐘:2026/11/14 14:16 EST
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
20.82 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.53/2.71
|
|
企業價值
36.36B
|
| 資產負債 |
|
每股賬面淨值
11.94
|
| 現金流量 |
|
現金流量率
0.10
|
| 損益表 |
|
收益
14.74B
|
|
每股收益
13.49
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up one-third of Viatris' total sales. The remaining sales are derived from its portfolio of legacy products, including Lipitor, Norvasc, Lyrica, and Viagra. |
